Dyne Therapeutics (DYN) Stock Forecast & Price Target

Dyne Therapeutics is viewed positively because the pooled ACHIEVE data showed consistent functional gains across multiple measures, including vHOT, 5xSTS, QMT, and MDHI, while also diverging from matched END-DM1 natural history for the first time. The safety profile remains supportive, with 143 patient-years and no related serious TEAEs, and the company is now advancing HARMONIA, a 150-patient phase III study across more than 35 global sites that is designed around a differentiating 5xSTS primary endpoint. The investment case is further strengthened by FORCE platform evidence of CNS delivery and by the DMD program’s January 2027 regulatory catalyst, while the cited framework still assigns meaningful implied upside if z-rostudirsen can approach peak risk-unadjusted sales of about $1B.

Dyne Therapeutics is viewed skeptically because its DM1 program still faces a fragile statistical case: the ACHIEVE-REC design remains small at N=71, while a natural-history analysis suggests placebo vHOT variability could cut power to about 55% from 90%+ and obscure a roughly 3-second treatment effect. The thesis is further weakened by the lack of individual-patient splicing data, weak correlation between splicing and functional benefit, and the possibility that even a primary-endpoint win may not generate convincing secondary or regulatory support. As a pre-commercial company with no product revenue and ongoing cash burn, it may need dilutive financing, while prior DM1 setbacks and competitive pressure add to execution and valuation risk.